Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946301 | 0.98 | ALDH1A1 (0.41) | POLBSMN1; SMN2ALDH1A1TSHRHDAC6 | |
| SCHEMBL18007187 | 0.94 | ALDH1A1 (0.38) | POLBSMN1; SMN2ALDH1A1TSHRHDAC6 | |
| SCHEMBL20606549 | 0.83 | HRH4 (0.42) | ALDH1A1TSHRHDAC6MAPK1USP2 | |
| SCHEMBL16792009 | 0.81 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1TSHRHDAC6USP2 | |
| SCHEMBL15330361 | 0.81 | HTR3A (0.46) | ALDH1A1TSHRHDAC6MAPK1USP2 | |
| SCHEMBL5525017 | 0.81 | POLB (0.57) | POLBALDH1A1TSHRHDAC6MAPK1 | |
| SCHEMBL16793545 | 0.81 | PTPN11 (0.38) | POLBALDH1A1 | |
| SCHEMBL18150782 | 0.79 | SMO (0.40) | POLBCYP2C19MAPT | |
| SCHEMBL2561983 | 0.79 | AOC3 (0.35) | SMN1; SMN2USP2MEN1CYP2C19KMT2A | |
| SCHEMBL17202032 | 0.78 | TRPV3 (0.40) | POLBSMN1; SMN2TSHRMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10117948-B2 | Selective arylation of dichalcogenides in biomolecules | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-11-06 | — | — | US | disclosed |
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3226867-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | Ananthan, Subramaniam (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160367693-A1 | Selective Arylation of Dichalcogenides in Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| WO-2016205798-A1 | SELECTIVE ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10117948-B2 | Selective arylation of dichalcogenides in biomolecules | SCLY, SELENOI, PTMS | POLB 4297/4885SMN1; SMN2 3613/4885ALDH1A1 3379/4885 |
| US-20160367693-A1 | Selective Arylation of Dichalcogenides in Biomolecules | SCLY, SELENOI, TPO | POLB 3485/4885SMN1; SMN2 2974/4885ALDH1A1 3721/4885 |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | POLB 4104/4885SMN1; SMN2 3258/4885ALDH1A1 1143/4885 |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | POLB 2322/4885SMN1; SMN2 1029/4885ALDH1A1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.